Understanding the Tip:
Why site changes impact stability programs:
Changing a manufacturing site mid-way through a stability program can introduce variability in material attributes, processing conditions, packaging operations, and environmental factors. Even if specifications remain constant, slight shifts in excipients, equipment, or personnel can affect the stability profile. Bridging protocols serve as a scientific roadmap to justify data continuity and support regulatory acceptance of site-transferred product batches.
Consequences of omitting bridging studies during site transfer:
Without a bridging protocol, regulators may question the applicability of previously generated data to the new site, especially for ongoing stability studies tied to shelf-life or product registration. This can delay approvals, lead to rejection of existing data, or require repeat studies—all of which affect cost, time, and compliance posture.
Regulatory and Technical Context:
ICH and WHO expectations for post-approval changes:
ICH Q1A(R2), Q5C, and WHO TRS 1010 recognize the importance of demonstrating equivalence when product manufacturing is transferred. ICH Q12 formalizes lifecycle management expectations, including requirements for comparability and continued stability evaluation post-change. Bridging studies, when properly designed, satisfy regulatory requirements for data reliability across site transitions.
CTD and audit implications:
In CTD Module 3.2.P.8.3, stability data used to justify shelf life and release conditions must reflect the commercial manufacturing process and site.
Best Practices and Implementation:
Develop a bridging protocol tailored to the change scope:
The protocol should include:
- Objective of the study (e.g., site comparability)
- Batches involved (pre-change and post-change)
- Study design (e.g., parallel storage under identical conditions)
- Parameters to be tested (assay, impurities, pH, dissolution, appearance, etc.)
- Evaluation criteria and acceptance limits
Define time points (e.g., 0, 3, 6, 9 months) and reference previously validated analytical methods for consistency.
Ensure alignment with regulatory filing strategies:
If the site change affects an approved product, submit the bridging protocol as part of a variation or supplement. Justify the study design and include commitment timelines for follow-up data. For new registrations, include protocol rationale in CTD Module 3.2.R and reference bridging outcomes in P.8.3 (stability summary). If comparability is demonstrated early, full-term studies may not be required for all new-site batches.
Manage QA and documentation throughout the transition:
QA must oversee:
- Protocol approval and implementation
- Sample pull and testing schedules
- Deviation tracking and data review
- Final bridging summary with statistical evaluation (e.g., t-tests, control charts)
Store all bridging-related data in dedicated folders linked to change control records and regulatory submissions.
Bridging protocols are not just a compliance formality—they are a proactive quality and regulatory strategy that ensures product continuity, supports faster approvals, and builds confidence in your pharmaceutical supply chain resilience.